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Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP
guidelines: a single institution analysis.
Testo
Background
HER2 overexpression occurs in approximately 15-20% of invasive breast cancers (BC). From a pathological point of view HER2
positivity is defined by intense circumferential membrane  complete staining in more than 10% of tumour cells in
immunohistochemistry (IHC score 3+). When complete circumferential staining is weak to moderate (IHC score 2+) double
probe in situ ibridation (ISH) is mandatory to define HER2 status. In 2018 ASCO/CAP guidelines were updated to provide
additional guidance in HER2 equivocal cases to allow a greater discrimination between positive and negative cases. Our aim is to




253 cases of early BC diagnosed at Modena Cancer Center between November 2013 and August 2017 were identified. Stage,
ISH result, hormonal receptor status (HR), proliferation index (MIB1), and histological grade were captured; menopausal status
was available too.  All IHC score 2+ cases were reclassified according to 2018 ASCO/CAP guidelines. The association between
pathological tumour features, clinical characteristics and ISH positivity was assessed using Fisher test.
 
Results
Overall, 25.7% IHC score 2+ BC resulted HER2 amplified in double probe ISH. High tumour grade (G3 vs G1-2) and MIB1 >
20% significantly predict HER2 ISH amplification (p=0,0001). No correlation was found according to HR, stage, or menopausal
status.
The majority (185; 98.4%) of HER2-ve BC were reclassified as group 5 (HER2/CEP17 ratio <2 and HER2 copy number <4
signals/cell) except for 3 specimens classified as group 4 (HER2/CEP17 RATIO <2 and HER2 copy number ³4 but <6
signals/cell). In HER2+ve group the majority (62; 95.3%) specimens were group 1 (HER2/CEP17 RATIO >2 and HER2 copy
number =4 signals/cell), no specimen was group 2, and only 3 cases were classified as group 3 (HER2/CEP17 RATIO <2 and
HER2 copy number >6 signals/cell). 
 
Conclusion
In this IHC score 2+ BC series, reclassification according to 2018 ASCO/CAP guidelines identified only 4.6% group 3 and 1.6%
group 4 cases. The routinely assessment of grading and proliferation index could help to predict HER2 amplification in IHC
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